{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:13:42Z","timestamp":1792242822277,"version":"4.4.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Evidence of the clinical benefit of pharmacogenetics-informed treatment (PIT) with antidepressants is still limited. Especially for tricyclic antidepressants (TCAs), pharmacogenetics may be of interest because therapeutic plasma concentrations are well defined, identification of optimal dosing can be time consuming, and treatment is frequently accompanied by adverse effects.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine whether PIT results in faster attainment of therapeutic TCA plasma concentrations compared with usual treatment in patients with unipolar major depressive disorder (MDD).<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This randomized clinical trial compared PIT with usual treatment among 111 patients at 4 centers in the Netherlands. Patients were treated with the TCAs nortriptyline, clomipramine, or imipramine, with clinical follow-up of 7 weeks. Patients were enrolled from June 1, 2018, to January 1, 2022. At inclusion, patients had unipolar nonpsychotic MDD (with a score of \u226519 on the 17-item Hamilton Rating Scale for Depression [HAMD-17]), were aged 18 to 65 years, and were eligible for TCA treatment. Main exclusion criteria were a bipolar or psychotic disorder, substance use disorder, pregnancy, interacting comedications, and concurrent use of psychotropic medications.<\/jats:p><\/jats:sec>Intervention<\/jats:title>In the PIT group, the initial TCA dosage was based on CYP2D6<\/jats:italic> and CYP2C19<\/jats:italic> genotypes. The control group received usual treatment, which comprised the standard initial TCA dosage.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was days until attainment of a therapeutic TCA plasma concentration. Secondary outcomes were severity of depressive symptoms (measured by HAMD-17 scores) and frequency and severity of adverse effects (measured by Frequency, Intensity, and Burden of Side Effects Rating scores).<\/jats:p><\/jats:sec>Results<\/jats:title>Of 125 patients randomized, 111 (mean [SD] age, 41.7 [13.3] years; 69 [62.2%] female) were included in the analysis; of those, 56 were in the PIT group and 55 were in the control group. The PIT group reached therapeutic concentrations faster than the control group (mean [SD], 17.3 [11.2] vs 22.0 [10.2] days; Kaplan-Meier \u03c72<\/jats:sup><\/jats:italic>1<\/jats:sub>\u2009=\u20094.30; P<\/jats:italic>\u2009=\u2009.04). No significant difference in reduction of depressive symptoms was observed. Linear mixed-model analyses showed that the interaction between group and time differed for the frequency (F<\/jats:italic>6,125<\/jats:sub>\u2009=\u20094.03; P<\/jats:italic>\u2009=\u2009.001), severity (F<\/jats:italic>6,114<\/jats:sub>\u2009=\u20093.10; P<\/jats:italic>\u2009=\u2009.008), and burden (F<\/jats:italic>6,112<\/jats:sub>\u2009=\u20092.56; P<\/jats:italic>\u2009=\u2009.02) of adverse effects, suggesting that adverse effects decreased relatively more for those receiving PIT.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this randomized clinical trial, PIT resulted in faster attainment of therapeutic TCA concentrations, with potentially fewer and less severe adverse effects. No effect on depressive symptoms was observed. These findings indicate that pharmacogenetics-informed dosing of TCAs can be safely applied and may be useful in personalizing treatment for patients with MDD.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03548675<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.12443","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:34:04Z","timestamp":1683563644000},"page":"e2312443","source":"Crossref","is-referenced-by-count":44,"title":["Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Cornelis F.","family":"Vos","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie E.","family":"ter Hark","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt F. A.","family":"Schellekens","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Nijmegen Institute for Scientist Practitioners in Addiction, Radboud University, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Spijker","sequence":"additional","affiliation":[{"name":"Depression Expertise Centre, Pro Persona, Nijmegen, the Netherlands"},{"name":"Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"van der Meij","sequence":"additional","affiliation":[{"name":"Depression Expertise Centre, Pro Persona, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne J.","family":"Grotenhuis","sequence":"additional","affiliation":[{"name":"Dutch Depression Society, Amersfoort, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Mihaescu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Catharina Hospital, Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wietske","family":"Kievit","sequence":"additional","affiliation":[{"name":"Department of Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier","family":"Donders","sequence":"additional","affiliation":[{"name":"Department of Health Evidence, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. H.","family":"Coenen","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost G. E.","family":"Janzing","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"1","key":"zoi230383r1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.v102.1","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.","volume":"102","author":"Hicks","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"zoi230383r2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/cpt.v103.4","article-title":"Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.","volume":"103","author":"Bank","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"zoi230383r3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte\u2014an update of guidelines.","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"zoi230383r4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fpsyt.2020.00094","article-title":"Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going?","volume":"11","author":"van Westrhenen","year":"2020","journal-title":"Front Psychiatry"},{"issue":"12","key":"zoi230383r5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Pharmacogenomics in treatment of depression and psychosis: an update.","volume":"43","author":"Jukic","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"zoi230383r6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","article-title":"Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.","volume":"168","author":"Rush","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"10128","key":"zoi230383r7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"zoi230383r8","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/da.v28.7","article-title":"Star-D: lessons learned and future implications.","volume":"28","author":"Rush","year":"2011","journal-title":"Depress Anxiety"},{"issue":"6","key":"zoi230383r9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.","volume":"151","author":"Gillman","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"3","key":"zoi230383r10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis.","volume":"78","author":"Milosavljevic","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1-02","key":"zoi230383r11","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017.","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"zoi230383r12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-030-10949-3","article-title":"Tricyclic antidepressants and monoamine oxidase inhibitors: are they too old for a new look?","volume":"250","author":"Chockalingam","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"zoi230383r13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/FPC.0b013e3283649b9a","article-title":"Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting.","volume":"23","author":"Hall-Flavin","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"zoi230383r14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.jad.2018.08.056","article-title":"The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis.","volume":"241","author":"Rosenblat","year":"2018","journal-title":"J Affect Disord"},{"issue":"89","key":"zoi230383r15","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder.","volume":"16","author":"Winner","year":"2013","journal-title":"Discov Med"},{"issue":"5","key":"zoi230383r16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/tpj.2014.85","article-title":"Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.","volume":"15","author":"Altar","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"zoi230383r18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.595219","article-title":"Pharmacogenetics guidelines: overview and comparison of the DPWG, CPIC, CPNDS, and RNPGx guidelines.","volume":"11","author":"Abdullah-Koolmees","year":"2021","journal-title":"Front Pharmacol"},{"issue":"5","key":"zoi230383r19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/cpt.v107.5","article-title":"Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements.","volume":"107","author":"Shekhani","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"zoi230383r20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/15622975.2021.1878427","article-title":"Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.","volume":"22","author":"Eap","year":"2021","journal-title":"World J Biol Psychiatry"},{"issue":"1","key":"zoi230383r21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1186\/s12888-021-03490-x","article-title":"Tricyclic antidepressants for major depressive disorder: a comprehensive evaluation of current practice in the Netherlands.","volume":"21","author":"Vos","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"1","key":"zoi230383r22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jad.2012.07.008","article-title":"The effect of prolonged duration of untreated depression on antidepressant treatment outcome.","volume":"145","author":"Bukh","year":"2013","journal-title":"J Affect Disord"},{"issue":"1","key":"zoi230383r25","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"zoi230383r27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00131746-200603000-00002","article-title":"Self-rated global measure of the frequency, intensity, and burden of side effects.","volume":"12","author":"Wisniewski","year":"2006","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"zoi230383r29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.","volume":"25","author":"Rush","year":"2004","journal-title":"Control Clin Trials"},{"issue":"11","key":"zoi230383r31","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"1","key":"zoi230383r32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2515\/therapie:2004003","article-title":"Some aspects of genetic polymorphism in the biotransformation of antidepressants.","volume":"59","author":"Br\u00f8sen","year":"2004","journal-title":"Therapie"},{"issue":"6","key":"zoi230383r33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/JCP.0000000000001129","article-title":"Effects of pharmacogenetic screening for CYP2D6 among elderly starting therapy with nortriptyline or venlafaxine: a pragmatic randomized controlled trial (CYSCE trial).","volume":"39","author":"van der Schans","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"zoi230383r34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jpsychires.2022.03.057","article-title":"Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: a systematic review.","volume":"150","author":"Ter Hark","year":"2022","journal-title":"J Psychiatr Res"},{"key":"zoi230383r35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jad.2018.09.067","article-title":"A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder.","volume":"243","author":"Perlman","year":"2019","journal-title":"J Affect Disord"},{"key":"zoi230383r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2022.114535","article-title":"CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability.","volume":"312","author":"Jokovic","year":"2022","journal-title":"Psychiatry Res"},{"issue":"5","key":"zoi230383r37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1037\/pha0000334","article-title":"Pharmacogenetics and therapeutic drug monitoring of fluoxetine in a real-world setting: a PK\/PD analysis of the influence of (non-)genetic factors.","volume":"28","author":"Magalh\u00e3es","year":"2020","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1-3","key":"zoi230383r38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jad.2009.02.013","article-title":"Body weight as a predictor of antidepressant efficacy in the GENDEP project.","volume":"118","author":"Uher","year":"2009","journal-title":"J Affect Disord"},{"issue":"6","key":"zoi230383r39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/cpt.v112.6","article-title":"Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials.","volume":"112","author":"Brown","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi230383r40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"issue":"2","key":"zoi230383r41","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care randomized clinical trial.","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"zoi230383r42","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12910","article-title":"Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial.","volume":"80","author":"Thase","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"zoi230383r43","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1001\/jamapsychiatry.2018.0834","article-title":"On the marketing and use of pharmacogenetic tests for psychiatric treatment.","volume":"75","author":"Zubenko","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"zoi230383r44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.euroneuro.2022.04.007","article-title":"Evaluating study designs and treatment outcomes of antidepressant pharmacogenetic clinical trials\u2014challenges and future perspectives. a critical review.","volume":"59","author":"Minelli","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"zoi230383r45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jama.2022.10018","article-title":"Pharmacogenomic testing for next-step antidepressant selection: still a work in progress.","volume":"328","author":"Iosifescu","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"zoi230383r46","first-page":"27","article-title":"Relationship between baseline severity of depression and antidepressant treatment outcome.","volume":"44","author":"Henkel","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"zoi230383r23","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi230383r24","first-page":"134","volume-title":"Comprehensive Handbook of Psychological Assessment, Volume 2: Personality Assessment","author":"First","year":"2004"},{"key":"zoi230383r30","year":"2021"},{"key":"zoi230383r17","unstructured":"Dutch Pharmacogenomic Working Group. Phamacogenomic recommendations\u2014pharmacogenetica. Royal Dutch Pharmacist\u2019s Association. Updated 2022. Accessed December 29, 2022. https:\/\/www.knmp.nl\/"},{"key":"zoi230383r26","unstructured":"Health Institute of the Netherlands. Pharmacotherapeutic compass. Health Institute of the Netherlands; 2020. Accessed December 29, 2022. https:\/\/farmacotherapeutischkompas.nl"},{"key":"zoi230383r28","unstructured":"European Medicines Agency. Bioanalytical method validation\u2014scientific guideline. European Medicines Agency. January 1, 2011. Updated March 6, 2015. Accessed December 30, 2022. https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation-scientific-guideline"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804583\/vos_2023_oi_230383_1682948871.09139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T16:34:12Z","timestamp":1683563652000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804583"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.12443","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]}}}